Navigation Links
Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
Date:6/24/2009

SAN DIEGO, June 24 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a second Phase 2 clinical trial with a novel drug candidate for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection. The trial will enroll patients for whom treatment with approved standard of care treatments is not currently advised. Results from an earlier clinical trial in HCV patients who failed standard of care treatment are expected to be reported later this year.

CTS-1027 is an oral, small molecule compound that inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases or MMPs. CTS-1027 had previously been shown to be effective in multiple preclinical models of inflammatory liver disease and HCV infection.

The clinical trial is a double-blind, placebo-controlled trial testing an optimized dose of CTS-1027 alone or in combination with ribavirin. Dosing will last for up to twenty four weeks. The Company expects approximately 70 patients to be enrolled. The clinical trial will be conducted at up to twenty five medical centers in the U.S. Additional information

about the trial can be found at: www.clinicaltrials.gov (identifier NCT00925990) or http://clinicaltrials.gov/ct2/show/NCT00925990?term=cts1027&rank=2

"Our recent preclinical studies suggest that CTS-1027 treatment has the potential to impact the second phase of HCV virus inhibitory kinetics in patients. This phase is associated with the gradual reduction and replacement of HCV infected cells by uninfected liver cells. Interestingly, ribavirin is also postulated to have the greatest impact on HCV sec
'/>"/>

SOURCE Conatus Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
2. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
3. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
4. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
5. ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
6. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
7. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
8. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
9. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
10. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
11. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)...  Eli Lilly and Company (NYSE: LLY ) announced ... offer for up to $1.6 billion aggregate principal amount of ... notes who tendered, and did not validly withdraw, their notes ... time, on May 27, 2015 (the early tender ... eligible to receive the total consideration. The total consideration for ...
(Date:5/28/2015)... and HOUSTON , May 28, 2015 ... EPI) today reported financial results for the second quarter and ... specified otherwise, are expressed in Canadian dollars and in accordance ... Results ESSA recorded a net loss of ... ended March 31, 2015 (Q2-2015), compared to a net loss ...
(Date:5/28/2015)... 28, 2015 Research ... addition of Jain PharmaBiotech,s new report  "RNAi ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... silencing involves the use of double stranded ... material is processed into short 21-23 nucleotide ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
(Date:5/30/2015)... The results of a 40+ year study ... potential to cause mesothelioma, regardless of the volume of ... the Surviving Mesothelioma website. , The study conducted ... Poland found that, among the 138 cases of mesothelioma ... all of them happened at plants that had, at ...
(Date:5/30/2015)... New York (PRWEB) May 30, 2015 ... pay $100 million in punitive and compensatory damages ... plaintiff who suffered serious complications following implantation of ... to a verdict rendered on May 28th in ... million in compensatory damages after the jury found ...
(Date:5/30/2015)... 2015 Responding to surging demand from ... experienced OGAWA products while abroad, OGAWA-engineered massage products have ... A leader in the Asian health and wellness industry ... developer and manufacturer of health and wellness equipment. ... their products, health enthusiasts in Asia and Australia, as ...
(Date:5/30/2015)... The Brain Fitness Education seminar was ... Senior Enrichment Center, headed by 1Heart Client Care Manager ... Brain Fitness Program Director Tee Barr. , Senior residents ... there are many ways to enrich and further improve ... the different ways to overcome dementia and memory loss. ...
(Date:5/30/2015)... 30, 2015 San Luis Obispo ... is offering a free analysis and consultation for anyone ... with Disability Awareness Month, which was created by the ... the United States such as Polk recognize the proclamation, ... about the possibility of disability, as well as the ...
Breaking Medicine News(10 mins):Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 3Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 3Health News:San Luis Obispo Insurance Agent Susan Polk Offering Complementary Insurance Analysis In Honor Of Disability Awareness Month 2
... Cord Blood America, Inc., (OTC Bulletin Board: CBAI) ( ... has selected Somerville Associates, a 25 year-old public relations ... counsel for Cord Blood America, Inc., according to Matthew ... The agency will publicize Cord Blood America in ...
... Anthem Blue Cross implemented an across-the-board increase in Californai Medicare ... senior citizens to look for new ways to maximize healthcare ... ... Los Angeles, CA (PRWEB) March 20, 2009 -- Anthem Blue ...
... Reflex Plus surgical microscope from Endure Medical, Inc. represents a new ... ... March 20, 2009 -- Endure Medical ( www.enduremed.com ) has created ... excellent optical quality, exceptional red reflex and a price that is ...
... and also have an abnormality in the heart,s electrical cycle ... than people who do not have abnormal electrical activity at ... The study also provides a threshold at which the threat ... in women and 438 milliseconds in men have the worst ...
... Silver 2009 ADDY® Award for its multi-media drug education and prevention campaign ... public service announcements. , ... Los Angeles, Ca (PRWEB) March 19, 2009 ... to 60 seconds in duration, brings home the stark reality of what ...
... 20 , - On Average a ... and Poland Claim Worsening Quality of Sleep,Thanks to the Economy(1) , ... Making the Admission, Compared,to 17% of the UK(1) , ... Problems Sleeping,Over the Last 12 Months, but Only 19% of These ...
Cached Medicine News:Health News:Cord Blood America, Inc. Appoints Somerville Associates, Public Relations Counsel 2Health News:Seniors Seek to Reduce Healthcare Costs as Anthem Blue Cross Increases Premiums 2Health News:Endure Medical Redefines Ophthalmic Surgical Microscopes 2Health News:Abnormal EKG can predict death in stroke patients 2Health News:Foundation for the Drug-Free World Honored with Seven ADDY Awards 2Health News:New Survey Highlights the Significant Impact of the Economic Downturn on Europe's Sleep 2Health News:New Survey Highlights the Significant Impact of the Economic Downturn on Europe's Sleep 3Health News:New Survey Highlights the Significant Impact of the Economic Downturn on Europe's Sleep 4Health News:New Survey Highlights the Significant Impact of the Economic Downturn on Europe's Sleep 5
... relieve low back discomfort. Strong mesh elastic ... comfortable, custom fit. Optional metal stays may ... spine. Wide elastic adjustment panels provide varying ... easily accessed and adjusted. Simple hood and ...
... Newport® Hip Management Systems are designed and ... orthosis for your patients. Innovative new options ... is built on the most successful patented ... the adjustable clamping disk design and the ...
... Pelvic Brace is the solution to the ... off-the-shelf brace fits like a custom and ... minutes. The Bledsoe Simple Pelvic Brace limits ... and adduction in 15 increments from -30 ...
... Abduction and rotation for ... and fractures. Preset at ... adjustable flexion and extension ... back panel. Available in ...
Medicine Products: